Abstract

Late morbidity and death as a result of progressive coronary vascular obliteration remains a major unsolved problem after orthotopic heart transplantation. Various percutaneous catheter intervention (PCI) methods have been used to treat transplant coronary artery disease (CAD), but few reports have assessed the longitudinal results of these procedures. Of 1,440 cardiac transplant patients at University of California, Los Angeles, Medical Center, treated between 1984 and 2004, 65 patients who had undergone orthotopic heart transplantation underwent PCI on a total of 156 coronary artery lesions because of transplant CAD between July 1993 and August 2004. The procedural success rate was 93%. Angiographic follow-up was available for 42 patients and 101 lesions 9.5 +/- 5.8 months after PCI. The global restenosis rate was 36%. Multivariate analysis was used to assess 49 clinical, angiographic, and immunologic variables per lesion. The use of a cutting balloon increased the risk of restenosis (odds ratio 11.5, p <0.01) and the use of stents decreased the risk of restenosis (odds ratio 0.34, p <0.05) compared with other PCI methods. The restenosis rate with drug-eluting stents was 19%, lower than that with bare metal stents (31%). Of the 65 patients, 20 (31%) died within 1.9 +/- 1.8 years after PCI. The actuarial survival rate was 56% at 5 years after the first PCI. In conclusion, although the restenosis rate after PCI was higher than that in nontransplant patients with CAD, the immediate and long-term results were acceptable in this high-risk population. Despite the intense inflammation associated with transplant CAD, drug-eluting stents appeared to reduce the occurrence of restenosis. Compared with historical controls, PCI may also improve the actuarial survival rate of patients undergoing orthotopic heart transplantation.

Highlights

  • Transplant coronary artery disease (TCAD) remains the limiting factor in the survival of orthotopic heart transplantation (OHT) recipients.[1,2,3] The process is characterized by diffuse and multifocal heterogeneous myointimal hyperplasia.[4]

  • Focal stenosis due to TCAD can be treated with percutaneous coronary intervention (PCI), the restenosis rate is higher than when treating native CAD.[12,13,14,15,16,17]

  • Procedural success was defined as postprocedural lumen diameter stenosis of Ͻ50% without creatine phosphokinase elevation, Q-wave myocardial infarction, emergency bypass surgery, or death related to the present PCI

Read more

Summary

Introduction

Transplant coronary artery disease (TCAD) remains the limiting factor in the survival of orthotopic heart transplantation (OHT) recipients.[1,2,3] The process is characterized by diffuse and multifocal heterogeneous myointimal hyperplasia.[4] The only effective treatment for such diffuse disease is retransplantation. Retransplantation is limited by the scarcity of donor organs, and the survival rate after retransplantation is worse than that after initial transplantation.[5,6] Coronary artery bypass grafting is seldom possible because of the diffuse nature of the disease, and the long-term results have been disappointing.[7] Pharmacologic interventions to prevent TCAD development have been unsuccessful, but some agents, such as pravastatin[8,9,10] or simvastatin,[11] may prolong the event-free interval. Focal stenosis due to TCAD can be treated with percutaneous coronary intervention (PCI), the restenosis rate is higher than when treating native CAD.[12,13,14,15,16,17] Advances in immunosuppressive therapy, including rapamycin, and PCI technology with drug-eluting stents (DESs) may be expected to reduce the restenosis rate in TCAD.[18,19] The objective of this study was to analyze the outcome of OHT patients in whom a PCI procedure had been performed at our hospital for treatment of TCAD

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.